Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.

Pietro FerraraPaolo A CortesiDanilo Di LauraAldo P MaggioniLorenzo G Mantovani

Published in: Clinical drug investigation (2021)

Compared with aspirin alone, rivaroxaban plus aspirin is cost effective in preventing recurrent cardiovascular events in all patients with CAD or PAD, from the Italian perspective. These results could help clinicians and decision makers to develop improved strategies for cardiovascular disease prevention.

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
low dose
atrial fibrillation
venous thromboembolism
percutaneous coronary intervention
pulmonary embolism
coronary artery
type diabetes
cardiovascular risk factors
decision making
acute coronary syndrome
chemotherapy induced